Jefferies Financial Group Inc. Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Jefferies Financial Group Inc.

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 13, 2024	SELL	$171.37 - $283.23 $891,124 - $1.47 Million	-5,200 Reduced 83.87%	1,000 $267,000
Q4 2023 Feb 13, 2024	BUY	$120.4 - $237.13 $96,320 - $189,704	800 Added 14.81%	6,200 $1.43 Million
Q3 2023 Nov 14, 2023	SELL	$146.04 - $225.78 $73,020 - $112,890	-500 Reduced 8.47%	5,400 $788,000
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $632,028 - $967,200	3,100 Added 110.71%	5,900 $1.36 Million
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $646,968 - $859,824	2,800 New	2,800 $678,000

315

20M

824K

1.04M

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $4.65B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.